Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Galeterone + Gemcitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Galeterone||TOK-001|VN-124||Hormone - Anti-androgens 29||Galeterone functions both as an inhibitor of CYP17A1 and anti-androgen, as it binds the androgen receptor, acting as an competitive antagonist and also preventing Ar protein binding to chromatin and enhancing degradation of mutant Ar protein (PMID: 24874833, PMID: 31653008).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 13||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04098081||Phase II||Galeterone + Gemcitabine Galeterone||1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma||Recruiting||USA||0|